Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease

Launched by BERNER REHA ZENTRUM AG · Aug 31, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how patients with fibrotic interstitial lung disease (a type of lung condition that causes scarring in the lungs) can improve their self-efficacy and overall quality of life. Participants in the trial will be patients receiving either inpatient rehabilitation or outpatient care for their lung disease. They will complete questionnaires about their symptoms and quality of life at the beginning of the study and again after their treatment. The results will help researchers understand how patients feel about managing their condition and will assist in planning future educational programs aimed at improving self-management skills.

To be eligible for the trial, participants must be at least 18 years old and have a confirmed diagnosis of fibrotic interstitial lung disease. Patients must also provide written consent to participate. However, those who cannot understand the study procedures or who have a different lung condition called sarcoidosis will not be included. Participants can expect to share their experiences and receive support while contributing to important research that may lead to better management strategies for lung diseases in the future.

Gender

ALL

Eligibility criteria

• Inclusion criteria are:
• • For Berner Reha Zentrum only: Diagnosis of a FILD as major indication for pulmonary rehabilitation
• • For Inselspital only: Enrolled in Idiopathic interstitial Pneumonia (IIP) cohort study (Nr. 246/15 / PB_2016-01524) and agreed to further use of data for further research purpose
• • Age ≥ 18 years
• • Written informed consent
• Exclusion criteria are:
• • Cognitive inability or insufficient knowledge of project language (German) to follow informed consent or study procedures
• • Sarcoidosis